The ICD-10-CM block D65-D69 encompasses a complex group of disorders characterized by abnormalities in the hemostatic process, leading to a pathological tendency toward excessive bleeding or, in the case of Disseminated Intravascular Coagulation (DIC), a paradoxical state of systemic microvascular thrombosis followed by consumption coagulopathy. Hemostasis is a highly regulated system involving vascular integrity, platelet function, and the coagulation cascade. This block includes hereditary deficiencies of specific clotting factors, such as Factor VIII (Hemophilia A) and Factor IX (Hemophilia B), as well as von Willebrand disease, which is the most common inherited bleeding disorder. It also covers acquired defects such as those resulting from vitamin K deficiency, liver disease, or drug-induced inhibitors. Furthermore, the block addresses purpura and platelet-related conditions, including immune thrombocytopenic purpura (ITP) and qualitative platelet defects, which manifest primarily as mucocutaneous bleeding. Management of these conditions often requires specialized hematological assessment, factor replacement therapy, and close monitoring of coagulation profiles.
Distinguish between hereditary and acquired coagulation defects to ensure accurate HCC mapping.
Example: Patient with established Hereditary factor VIII deficiency (D66) presenting with acute hemarthrosis of the right knee. Laboratory results show factor VIII activity level at less than 1 percent, confirming severe phenotype. No factor VIII inhibitors detected via Bethesda assay. Documentation includes chronic condition status and its impact on the current acute bleeding episode, supporting high-severity risk adjustment.
Billing Focus: Identify the specific factor deficiency and whether it is a congenital or acquired condition.
Document the presence of factor inhibitors explicitly as they necessitate different treatment modalities and coding.
Example: Patient with Hemophilia A and a known high-titer Factor VIII inhibitor (D68.1) presenting for routine prophylaxis. Current management involves bypassing agents. Documentation notes the inhibitor status complicates surgical planning and routine bleeding management, justifying moderate to high complexity MDM for an established patient (99214 or 99215).
Billing Focus: Use secondary codes for inhibitors (D68.1) alongside the primary coagulation defect code.
For thrombocytopenia and purpura, specify the etiology such as immune-mediated, secondary to drugs, or unspecified.
Example: Patient diagnosed with Chronic Immune thrombocytopenic purpura (D69.3) with a current platelet count of 22,000 per microliter. Patient is currently on second-line therapy with Romiplostim. Documentation excludes secondary causes such as Heparin-Induced Thrombocytopenia (D74.821) or drug-induced causes (D69.59), ensuring correct primary diagnosis coding.
Billing Focus: Avoid using D69.6 (Thrombocytopenia, unspecified) when the cause (e.g., Immune-mediated) is known.
Specify the type and severity of von Willebrand disease to capture the clinical complexity.
Example: Patient with Type 2B von Willebrand disease (D68.022) presenting for preoperative clearance. History of severe mucosal bleeding requiring Desmopressin and VWD factor concentrate. Documentation clearly distinguishes this from Type 1 (D68.01) to ensure the specific pathophysiology and treatment risks are captured.
Billing Focus: Use the fifth or sixth digit specificity for VWD types (Type 1, 2A, 2B, 2M, 2N, 3).
Clarify the relationship between anticoagulant use and hemorrhagic conditions.
Example: Patient on long-term Apixaban for atrial fibrillation presenting with extensive ecchymosis and hematuria. Diagnosis is Hemorrhagic disorder due to extrinsic circulating anticoagulants (D68.32). Documentation links the bleeding directly to the medication use and includes the management of the supratherapeutic state.
Billing Focus: Ensure the specific anticoagulant class (e.g., Vitamin K antagonist vs. direct oral anticoagulant) is reflected in the record.
Typically used for managing stable but complex bleeding disorders or those requiring medication adjustments.
Appropriate for patients with acute bleeding, factor inhibitors, or life-threatening thrombocytopenia requiring immediate intervention.
Essential for diagnosing and monitoring Hemophilia A (D66).
Diagnostic test for von Willebrand disease (D68.01-D68.09).
Used for clinical administration of factor concentrates or IVIG.
Primary tool for monitoring platelet counts in purpura (D69.3).
Prolonged in Hemophilia A and B and certain VWD types.
Required when inhibitors are suspected in hemophilia patients (D68.1).
Used to diagnose qualitative platelet defects (D69.1).
A treatment option for refractory ITP (D69.3) to prevent platelet destruction.